Research Leader Named to Rutgers Cancer Institute from National Cancer Institute to Build World-Class Cancer Immunology and Immunotherapy Programs

Research Leader Christian Hinrichs, MD, has been named Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey,

Read more

Rutgers Cancer Institute of New Jersey Receives $25 Million Gift for Cancer Immunology and Metabolism Center of Excellence

A $25 million transformational gift given to Rutgers Cancer Institute will provide critical support for the Cancer Immunology and Metabolism Center of Excellence to help scientists better understand the human immune response to cancer and ultimately develop the foundation for new treatments or make existing therapies more effective.

Read more

Safely Donate Blood This Winter

With the added concern of COVID-19 safety, there will be drop in the donation of critically needed blood throughout the United States, which is typically low during the winter months. Expert from Rutgers Cancer Institute of New Jersey urges giving the gift of life by donating blood.

Read more

More Joy, Less Stress: Coping With Cancer through the Holiday Season

The holiday season can be challenging for those impacted by cancer. This time may be especially demanding and draining, creating mixed emotions and added stress due to the COVID-19 pandemic. Expert from Rutgers Cancer Institute of New Jersey provides some strategies to consider for less stress this holiday season.

Read more

Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients

Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.

Read more

Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma

Older individuals are at an increased risk of developing primary central nervous system lymphoma (PCNSL). In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute of New Jersey and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.

Read more

Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.

Read more

Exploration of Genomic Ancestry in B-Cell Malignancies Identifies Multiple Important Genomic Differences

Investigators from Foundation Medicine, Inc. and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, examined genomic ancestry in BCL subtypes applying genomic ancestry prediction methodology to comprehensive genomic profiling data and found multiple genomic differences. Results of the study will be shared at the virtual American Society of Hematology Annual Meeting.

Read more

Rutgers Cancer Institute of New Jersey to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition

The American Society of Hematology (ASH), is the world’s largest professional society with a focus on the causes and treatment of blood disorders. Experts from Rutgers Cancer Institute of New Jersey will be presenting a variety of key hematology data at the 62nd American Society of Hematology Annual Meeting. This includes 22 scheduled presentations, including 10 oral presentations examining several types of blood cancers including leukemia, lymphoma, and myeloma.

Read more

Exploring the Role of Tumor Suppressor Enhancers in the Development of T-cell Acute Lymphoblastic Leukemia

Researchers from Rutgers Cancer Institute of New Jersey identified a novel enhancer that interacts with a tumor suppressor gene and explored its involvement in normal T-cell development as well as in T-cell acute lymphoblastic leukemia (T-ALL).

Read more